Erratum to 'Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial': [ESMO Open Volume 6, Issue 3, June 2021, 100101]

Affiliations

• ¹ Department of Medical Oncology, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA. Electronic address: toni_choueiri@dfci.harvard.edu.
• ² Renal and Skin Units, The Royal Marsden NHS Foundation Trust, Chelsea, London, UK.
• ³ Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, USA.
• ⁴ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
• ⁵ Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, USA.
• ⁶ Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK.
• ⁷ P. Hertsen Moscow Oncology Research Institute, Moscow, Russia.
• ⁸ Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
• ⁹ Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Université, Inserm, CNRS, CRCM, Marseille, France.
• ¹⁰ Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, USA.
• ¹¹ Oncology, Pfizer, New York, USA.
• ¹² Oncology, Pfizer, Cambridge, USA.
• ¹³ Computational Biology, Pfizer, San Diego, USA.
• ¹⁴ Immuno-Oncology, Pfizer, Milan, Lombardia, Italy.
• ¹⁵ Translational Oncology, Pfizer, San Diego, USA.
• ¹⁶ Biostatistics, Pfizer, Groton, USA.
• ¹⁷ Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.